Home  |  Contact

UniProtKB/Swiss-Prot Q14654: Variant p.Arg50Pro

ATP-sensitive inward rectifier potassium channel 11
Gene: KCNJ11
Variant information

Variant position:  50
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Type of variant:  LP/P [Disclaimer]
The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance

Residue change:  From Arginine (R) to Proline (P) at position 50 (R50P, p.Arg50Pro).
Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.

Physico-chemical properties:  Change from large size and basic (R) to medium size and hydrophobic (P)
The physico-chemical property of the reference and variant residues and the change implicated.

BLOSUM score:  -2
The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page

Variant description:  In PNDM2; decreased inhibition by ATP; enhanced activation by Mg(2+); increased current.
Any additional useful information about the variant.

Other resources:  
Links to websites of interest for the variant.



Sequence information

Variant position:  50
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Protein sequence length:  390
The length of the canonical sequence.

Location on the sequence:   QRRARFVSKKGNCNVAHKNI  R EQGRFLQDVFTTLVDLKWPH
The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.

Residue conservation: 
The multiple alignment of the region surrounding the variant against various orthologous sequences.

Human                         QRRARFVSKKGNCNVAHKNIREQGRFLQDVFTTLVDLKWPH

Mouse                         ERRARFVSKKGNCNVAHKNIREQGRFLQDVFTTLVDLKWPH

Rat                           ERRARFVSKKGNCNVAHKNIREQGRFLQDVFTTLVDLKWPH

Rabbit                        ERRARFVSKKGNCNVAHKNIREQGRFLQDVFTTLVDLKWTH

Sequence annotation in neighborhood:  
The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.

TypePositionsDescription
Chain 1 – 390 ATP-sensitive inward rectifier potassium channel 11
Topological domain 1 – 68 Cytoplasmic
Alternative sequence 1 – 87 Missing. In isoform 2.
Mutagenesis 64 – 64 V -> M. Displays gain of function; increased open state stability, reduced ATP sensitivity and increased channel activity; almost completely abolishes high affinity sensitivity to glibenclamide, an inhibitor of ATP-sensitive potassium channels.


Literature citations

KCNJ11 activating mutations in Italian patients with permanent neonatal diabetes.
Massa O.; Iafusco D.; D'Amato E.; Gloyn A.L.; Hattersley A.T.; Pasquino B.; Tonini G.; Dammacco F.; Zanette G.; Meschi F.; Porzio O.; Bottazzo G.; Crino A.; Lorini R.; Cerutti F.; Vanelli M.; Barbetti F.;
Hum. Mutat. 25:22-27(2005)
Cited for: VARIANTS PNDM2 PRO-50; MET-59; ARG-170; ASN-170 AND CYS-201;

Mutations at the same residue (R50) of Kir6.2 (KCNJ11) that cause neonatal diabetes produce different functional effects.
Shimomura K.; Girard C.A.J.; Proks P.; Nazim J.; Lippiat J.D.; Cerutti F.; Lorini R.; Ellard S.; Hattersely A.T.; Barbetti F.; Ashcroft F.M.;
Diabetes 55:1705-1712(2006)
Cited for: VARIANTS PNDM2 GLN-50 AND PRO-50; CHARACTERIZATION OF VARIANTS PNDM2 GLN-50 AND PRO-50;

Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.